Europe - FRA:56S1 - FR0013154002 - Common Stock
56S1 gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 20 industry peers in the Life Sciences Tools & Services industry. 56S1 has an average financial health and profitability rating. 56S1 is quite expensive at the moment. It does show a decent growth rate.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.35% | ||
| ROE | 6.54% | ||
| ROIC | 5.94% | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.63% | ||
| PM (TTM) | 8.96% | ||
| GM | 45.64% | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.84 | ||
| Altman-Z | 4.45 | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.5 | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 59.2 | ||
| Fwd PE | 38.61 | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 53.85 | ||
| EV/EBITDA | 27.77 | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.33% | 
FRA:56S1 (10/30/2025, 7:00:00 PM)
207.2
-1.7 (-0.81%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.33% | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 59.2 | ||
| Fwd PE | 38.61 | ||
| P/S | 6.84 | ||
| P/FCF | 53.85 | ||
| P/OCF | 27.6 | ||
| P/B | 5 | ||
| P/tB | N/A | ||
| EV/EBITDA | 27.77 | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.35% | ||
| ROE | 6.54% | ||
| ROCE | 7.46% | ||
| ROIC | 5.94% | ||
| ROICexc | 6.26% | ||
| ROICexgc | 21.64% | ||
| OM | 16.63% | ||
| PM (TTM) | 8.96% | ||
| GM | 45.64% | ||
| FCFM | 12.71% | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.84 | ||
| Debt/EBITDA | 2.5 | ||
| Cap/Depr | 113.12% | ||
| Cap/Sales | 12.09% | ||
| Interest Coverage | 3.09 | ||
| Cash Conversion | 90.78% | ||
| Profit Quality | 141.8% | ||
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.5 | ||
| Altman-Z | 4.45 | 
ChartMill assigns a fundamental rating of 5 / 10 to 56S1.DE.
ChartMill assigns a valuation rating of 2 / 10 to SARTORIUS STEDIM BIOTECH (56S1.DE). This can be considered as Overvalued.
SARTORIUS STEDIM BIOTECH (56S1.DE) has a profitability rating of 6 / 10.
The financial health rating of SARTORIUS STEDIM BIOTECH (56S1.DE) is 4 / 10.
The dividend rating of SARTORIUS STEDIM BIOTECH (56S1.DE) is 4 / 10 and the dividend payout ratio is 25.41%.